Modulation of Interleukin-12 activity in the presence of heparin

被引:0
|
作者
Srinivas Jayanthi
Bhanu prasanth Koppolu
Khue G. Nguyen
Sean G. Smith
Barbara K. Felber
Thallapuranam Krishnaswamy Suresh Kumar
David A. Zaharoff
机构
[1] University of Arkansas,Department of Chemistry and Biochemistry
[2] University of Arkansas,Department of Biomedical Engineering
[3] North Carolina State University and the University of North Carolina-Chapel Hill,Joint Department of Biomedical Engineering
[4] University of Arkansas,Cell and Molecular Biology Program
[5] University of North Carolina,Department of Microbiology and Immunology
[6] Vaccine Branch-National Cancer Institute,Human Retrovirus Pathogenesis Section
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Glycosaminoglycans (GAGs), especially heparin and heparan sulfate (HS), modulate the functions of numerous cytokines. The aims of this multidisciplinary research were to characterize heparin binding to interleukin-12 (IL-12) and determine the mechanism(s) by which heparin influences IL-12 bioactivity. Heparin and HS were found to bind human IL-12 (hIL-12) with low micromolar affinity and increase hIL-12 bioactivity by more than 6-fold. Conversely, other GAGs did not demonstrate significant binding, nor did their addition affect hIL-12 bioactivity. Biophysical studies demonstrated that heparin induced only minor conformational changes while size-exclusion chromatography and small angle X-ray scattering studies indicated that heparin induced dimerization of hIL-12. Heparin modestly protected hIL-12 from proteolytic degradation, however, this was not a likely mechanism for increased cytokine activity in vitro. Flow cytometry studies revealed that heparin increased the amount of hIL-12 bound to cell surfaces. Heparin also facilitated hIL-12 binding and signaling in cells in which both hIL-12 receptor subunits were functionally deleted. Results of this study demonstrate a new role for heparin in modulating the biological activity of IL-12.
引用
收藏
相关论文
共 50 条
  • [31] Interleukin-12 in infectious diseases
    Romani, L
    Puccetti, P
    Bistoni, F
    CLINICAL MICROBIOLOGY REVIEWS, 1997, 10 (04) : 611 - +
  • [32] Interleukin-12 Message in a Bottle
    Cirella, Assunta
    Berraondo, Pedro
    Di Trani, Claudia Augusta
    Melero, Ignacio
    CLINICAL CANCER RESEARCH, 2020, 26 (23) : 6080 - 6082
  • [33] PRODUCER CELLS OF INTERLEUKIN-12
    TRINCHIERI, G
    RENGARAJU, M
    DANDREA, A
    VALIANTE, NM
    KUBIN, M
    ASTE, M
    CHEHIMI, J
    IMMUNOLOGY TODAY, 1993, 14 (05): : 237 - 238
  • [34] INTERLEUKIN-12 TREATMENT OF RETINOBLASTOMA
    GEER, DC
    OBRIEN, JM
    SMITH, BJ
    MURRAY, TG
    VALOR, NL
    KSANDER, BR
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1995, 36 (04) : S773 - S773
  • [35] MOLECULAR CHARACTERIZATION OF INTERLEUKIN-12
    PODLASKI, FJ
    NANDURI, VB
    HULMES, JD
    PAN, YCE
    LEVIN, W
    DANHO, W
    CHIZZONITE, R
    GATELY, MK
    STERN, AS
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1992, 294 (01) : 230 - 237
  • [36] Interleukin-12: Amiss in MS
    Karp, CL
    ANNALS OF NEUROLOGY, 1999, 45 (06) : 689 - 692
  • [37] INTERLEUKIN-12: A CONCISE OVERVIEW
    王宜强
    实验血液学杂志, 1995, (01) : 1 - 9
  • [38] Interleukin-12 and the development of atopy
    Camporota, L
    CLINICAL AND EXPERIMENTAL ALLERGY, 2001, 31 (10): : 1481 - 1484
  • [39] Interleukin-12 and malaria - Comment
    Scott
    RESEARCH IN IMMUNOLOGY, 1995, 146 (7-8): : 559 - 559
  • [40] Interleukin-12 in human milk
    Bryan, DL
    Hawkes, JS
    Gibson, RA
    PEDIATRIC RESEARCH, 1999, 45 (06) : 858 - 859